madman
Super Moderator
Abraham Morgentaler, MD, Blavatnik Faculty Fellow in Health and Longevity at Beth Israel Deaconess Medical Center and Harvard University in Boston, MA, shares results of his article appearing in the November 2024 issue of Mayo Clinic Proceedings, where he and his colleagues found definitive evidence that no major adverse cardiovascular events result from testosterone therapy in men when compared with a large, matched placebo cohort. Dr. Morgentaler notes patients can be assured this therapy is safe with regard to cardiovascular risk and clinicians need no longer restrict use of testosterone therapy because of concerns regarding cardiovascular risk. Future research should now explore potential benefits of testosterone therapy for both men and women, as suggested by prior research.
